spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  PROVENGE 

 HSMN NewsFeed - 24 Jun 2019
BioEclipse Therapeutics(TM) Announces Appointment of New Directors and Series A-1 Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 17 Sep 2013
Dendreon Announces Marketing Authorization for PROVENGE(R) in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Jun 2013
Dendreon Receives Positive Opinion for PROVENGE(R) in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Feb 2012
Dendreon Announces CEO and Chairman Succession Plan
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Nov 2011
Dendreon Announces the Centers for Medicare and Medicaid Services (CMS) Will Now Cover Infusion Costs Associated with the Administration of PROVENGE
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 31 Aug 2011
Dendreon Appoints John E. Osborn EVP & General Counsel
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Jun 2011
Genesis Biopharma Names Martin Schroeder to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Mar 2011
PhaseRx Appoints Richard P. Rieger Vice President, Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jul 2010
Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2010
Allostera Pharma Inc. Appoints Christopher Henney as Chairman of its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Apr 2009
Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2009
PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2008
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Feb 2008
Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
Dendreon Announces FDA Confirms Data Required for Provenge(R) Licensure
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 May 2007
Dendreon Receives Complete Response Letter From FDA for Provenge(R) Biologics License Application
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Oct 2006
Dendreon Presents New Data Correlating Potency of PROVENGE to Survival in Phase 3 Studies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jun 2006
Dendreon Announces Publication of Pivotal Phase 3 Study Highlighting Survival Benefit and Safety Profile of PROVENGE in Men With Advanced Prostate Cancer
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 37

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 37 additional stories matching:
PROVENGE
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.